Division of Daiichi Sankyo Co. Ltd.
Latest From Protarga Inc.
Norwegian biotechnology company Clavis Pharma was spun out of Norsk Hydro in August 2001 to commercialize Lipid Vector Technology (LVT). LVT conjugates fatty acids to existing therapeutics to improve their ability to enter target cells. Clavis' first product is an LVT derivative of Ara-C, a common chemotherapy for blood cancers, which the firm is testing in solid tumor indications.
Sympore aims to develop new, improved versions of both existing medicines as well as novel drugs by elucidating and harnessing the natural mechanisms that underlie directed transport in the body.
- Therapeutic Areas
- Infectious & Viral Diseases
- Neurology, Nervous System
- Neuromedica Inc.
- North America
- Parent & Subsidiaries
- Daiichi Sankyo Co. Ltd.
- Senior Management
Nigel L Webb, PhD, Pres. & CEO
Robert Dickey IV, VP, Fin. & Corp. Dev. & CFO
Forrest Anthony, MD, PhD, VP, Clinical Dev.
- Contact Info
Phone: (610) 592-4000
2200 Renaissance Blvd.
King of Prussia, PA 19406
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.